• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report examines brand committees

Report examines brand committees

August 27, 2015
CenterWatch Staff

Life sciences organizations typically implement cross-functional brand commercialization committees to drive product development and maximize commercial success, according to a new study by pharmaceutical intelligence firm Cutting Edge Information. Those groups often are tasked with making key brand strategy decisions and with coordinating a broad range of brand activities throughout the product lifecycle.

The study “Pharmaceutical Commercialization Profiles: Driving Brand Success with Better Budgeting and Timing” found that commercialization committees include representatives from new product planning teams at 80% of surveyed companies. Sixty percent of surveyed companies have members from clinical development, legal and market research groups on those early-stage committees. Less than half of surveyed firms look to other internal functions during early brand development.

“As products mature, brand commercialization committees change as additional experts are called upon to drive brand decisions,” said Victoria Cavicchi, research analyst at Cutting Edge Information. “As these committees grow in size, so too does the number of teams represented.” By phase III, more than 50% of surveyed companies have representation from each function—from new product planning to medical affairs to market access to sales—on committees. All surveyed companies call on regulatory, pricing and reimbursement and marketing and commercial stakeholders.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing